An experimental regenerative therapy that Frequency Therapeutics was developing to treat a form of hearing loss has failed to beat a placebo in a clinical trial for the second time in two years, ...
Feb. 13 (UPI) --Regenerative medicine company Frequency Therapeutics announced Monday it will scrap development of a drug called FX-322, after testing failed to show improvement in speech perception ...
Frequency Therapeutics has raised $62 million to take its Astellas-partnered hearing loss drug into phase 2a studies. The series C round is the latest in a series of boosts for Frequency’s attempts to ...
Astellas Pharma will partner with Frequency Therapeutics to develop Frequency’s lead candidate—the Phase IIa-bound sensorineural hearing loss regenerative therapeutic FX-322—through a collaboration ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results